ANA598: Additional Phase II data

In an ongoing, double-blind, placebo-controlled, U.S. Phase II trial in 95 patients, all 6 patients who received 200 mg ANA598 plus standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus ribavirin) achieved an SVR 12 weeks after the end of treatment. All 6 patients achieved undetectable HCV viral load (HCV RNA <15 IU/mL) at weeks 4 and 12 and subsequently stopped all treatment at week 24.

In 18 evaluable patients receiving 200 mg ANA598 plus SOC who had undetectable HCV viral loads at week 24 and continued receiving SOC alone, all patients maintained undetectable HCV viral loads at week 36. Additionally, all 23 patients receiving 400 mg ANA598 plus SOC who had undetectable viral loads at week 12 and continued receiving SOC alone had undetectable viral loads at week 24. ...